Managed Healthcare Executive17h
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G.
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
Zacks.com on MSN14h
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
Fierce Pharma17h
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Fierce Pharma16h
Novartis links music and science in corporate campaign tied to Eurovision sponsorship
Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...
BioSpace17h
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
Daily Voice on MSN14h
Pharma Giant Cutting 400+ More NJ Jobs Ahead Of Major Drug Patent's Expiration
Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...
The American Journal of Managed Care18h
FDA Approves Oral Iptacopan for C3 Glomerulopathy
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
NJ-based Novartis to lay off 427 as drug patent expires
Global drugmaker Novartis will lay off 427 employees who report to the company's East Hanover headquarters this spring and ...
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs
Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...
Scientific American19h
Artificial Intelligence is Reshaping Healthcare
Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...
The American Journal of Managed Care18h
Overcoming CAR T Manufacturing Failure in LBCL
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...